$TXTM operates two wholly owned subsidiaries; Plan
Post# of 46489
(Total Views: 683)
Posted On: 09/11/2017 2:09:03 PM
$TXTM operates two wholly owned subsidiaries; Plandai Biotechnology South Africa (PTY) LTD. and Cannabis Biosciences, Inc. The Company is engaged in the research and clinical testing of bioceutical products, all natural ingredients formulated for pharmaceutical applications and processed under pharma-grade conditions.
Plandai Biotechnology SA, has the exclusive worldwide license to develop pharmaceutical applications and products using the Phytofare catechin complex, which was developed by Plandai Biotechnology, Inc. Phytofare is a highly bioavailable extract produced from live green tea leaves. Our initial product, Phytofare Catechin Complex, has been clinically shown to have 10 times greater bioavailability over generic catechin extracts.
Cannabis Biosciences is actively pursuing government licenses and permits that will allow it to use its proprietary processing and extraction technology to commence investigations and produce a full-profile cannabis extract, one that contains both CBD and the precursor acid form of THC (THC-A and THC-
found in live cannabis plant. The Company's investigations will be designed to show that the Cannabis Biosciences extraction process, which will use live leaf and low temperatures to extract the phyto-chemicals, should leave the acid forms of THC intact, resulting in a non-psychoactive extract with full medicinal potential and having the heightened bioavailability of other Phytofare extracts. Learn more at: http://www.protextm.co
Plandai Biotechnology SA, has the exclusive worldwide license to develop pharmaceutical applications and products using the Phytofare catechin complex, which was developed by Plandai Biotechnology, Inc. Phytofare is a highly bioavailable extract produced from live green tea leaves. Our initial product, Phytofare Catechin Complex, has been clinically shown to have 10 times greater bioavailability over generic catechin extracts.
Cannabis Biosciences is actively pursuing government licenses and permits that will allow it to use its proprietary processing and extraction technology to commence investigations and produce a full-profile cannabis extract, one that contains both CBD and the precursor acid form of THC (THC-A and THC-
found in live cannabis plant. The Company's investigations will be designed to show that the Cannabis Biosciences extraction process, which will use live leaf and low temperatures to extract the phyto-chemicals, should leave the acid forms of THC intact, resulting in a non-psychoactive extract with full medicinal potential and having the heightened bioavailability of other Phytofare extracts. Learn more at: http://www.protextm.co 
(0)
(0)Scroll down for more posts ▼